Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

29 Jul 2022

Abstract excerpt

BACKGROUND: The efficacy of bevacizumab in non-small cell lung cancer (NSCLC) patients is unsatisfactory, and the selection of suitable patients is still challenging. Given the epigenetic modifications can contribute to an aberrant regulation of angiogenesis and microenvironment, we investigated DNA methylation profiles to determine clinical benefit of bevacizumab in NSCLC patients. METHODS: Genome-wide DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35906610
DOI: 10.1186/s12885-022-09918-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancerPMID 35906610Read ↗

DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical managementSemantic proximity Read ↗

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast CancerSemantic proximity Read ↗

Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung CancerSemantic proximity Read ↗

A Novel Methylation-based Model for Prognostic Prediction in Lung AdenocarcinomaSemantic proximity Read ↗

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNASemantic proximity Read ↗

Pan-cancer analysis of DNMT3A as a robust prognostic biomarker to predict the immunotherapy responseSemantic proximity Read ↗

Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancerSemantic proximity Read ↗

Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutationsSemantic proximity Read ↗

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance predictionSemantic proximity Read ↗

Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma.Semantic proximity Read ↗

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.Semantic proximity Read ↗

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.